– May 6, 2010: Company receives orphan-drug designation from the FDA for AEZS-108 in ovarian cancer tumor. – May 12, 2010: FDA approves the Company’s Investigational New Medication software for AEZS-108 in LHRH-receptor positive urothelial tumor. Juergen Engel, Ph.D., Aeterna Zentaris’ President and Chief Executive Officer commented, It has been a very exciting quarter as we made great strides in the advancement of our business lead oncology compound, perifosine, today in Phase 3 sign up trials for multiple myeloma and refractory advanced colorectal cancer. Furthermore, the various designations lately granted by the FDA in both indications and the EMA’s positive Scientific Advice for multiple myeloma, will accelerate and also facilitate the future review and advertising authorization processes in North European countries and America.